HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.30M | -1.34M | -3.92M | -2.74M | -4.44M |
| Total Depreciation and Amortization | 5.54M | 5.46M | 5.51M | 5.48M | 5.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -614.00K | 139.00K | 1.62M | 578.00K | 670.00K |
| Change in Net Operating Assets | 3.74M | 2.24M | -739.00K | 1.28M | 1.95M |
| Cash from Operations | 6.37M | 6.51M | 2.48M | 4.60M | 3.54M |
| Capital Expenditure | -- | -33.00K | -64.00K | -87.00K | -21.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -383.00K | -283.00K | -215.00K | -1.00M | -- |
| Cash from Investing | -383.00K | -316.00K | -279.00K | -1.09M | -21.00K |
| Total Debt Issued | -- | 0.00 | 57.24M | -- | -- |
| Total Debt Repaid | -5.26M | -5.19M | -58.68M | -8.63M | -3.10M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -7.00K | -783.00K | -833.00K | -176.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -168.00K | -1.22M | -- | -- |
| Cash from Financing | -5.26M | -5.37M | -3.44M | -9.47M | -3.28M |
| Foreign Exchange rate Adjustments | -120.00K | 122.00K | -128.00K | 367.00K | 35.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 603.00K | 945.00K | -1.38M | -5.58M | 278.00K |